13 views0 min read
Mydecine Innovations Group gearing up for human trials after completing Aquis listing
London, UK --News Direct-- Mydecine Innovations Group Inc Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company's ambitious goals in the psychedelic medicine sector.Bartch explains that Mydecine focuses on developing "second generation" drugs de... Read More...